<SEC-DOCUMENT>0001615774-18-000606.txt : 20180129
<SEC-HEADER>0001615774-18-000606.hdr.sgml : 20180129
<ACCEPTANCE-DATETIME>20180129090037
ACCESSION NUMBER:		0001615774-18-000606
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20180129
FILED AS OF DATE:		20180129
DATE AS OF CHANGE:		20180129

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Immuron Ltd
		CENTRAL INDEX KEY:			0001660046
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38104
		FILM NUMBER:		18553610

	BUSINESS ADDRESS:	
		STREET 1:		62 LYGON STREET
		STREET 2:		LEVEL 3
		CITY:			CARLTON, VICTORIA
		STATE:			C3
		ZIP:			3053
		BUSINESS PHONE:		61 03 9824 5254

	MAIL ADDRESS:	
		STREET 1:		62 LYGON STREET
		STREET 2:		LEVEL 3
		CITY:			CARLTON, VICTORIA
		STATE:			C3
		ZIP:			3053
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>s108836_6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Form 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 UNDER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">For the Month of January 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Commission File Number: 001-38104</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>IMMURON LIMITED</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Name of Registrant)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>Level 3, 62 Lygon Street, Carlton South,
Victoria, 3053, Australia 3053 </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Address of principal executive office)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Form 20-F <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT>
Form 40-F <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark whether by furnishing the information contained
in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Yes <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
<FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">If &ldquo;Yes&rdquo; is marked, indicate below the file number assigned
to the registrant in connection with Rule 12g3-2(b): 82-</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Arial, Helvetica, Sans-Serif"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>IMMURON LIMITED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>EXPLANATORY NOTE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Immuron Limited (the &ldquo;Company&rdquo;) will be publishing an
announcement (the &ldquo;Public Notice&rdquo;) to the Australian Securities Exchange today January 30, 2018 announcing &lsquo;US
Defence Reports Travelan Targets Priority Pathogens&rsquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A copy of the Public Notice is attached as
an exhibit to this report on Form 6-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This report on Form 6-K (including the exhibit
hereto) shall not be deemed to be &ldquo;filed&rdquo; for purposes of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange
Act&rdquo;) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as
shall be expressly set forth by specific reference in such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>EXHIBITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Exhibit</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Number</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 92%; border-bottom: black 1pt solid"><BR>
<FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><A HREF="s108836_ex99-1.htm">99.1</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt"><A HREF="s108836_ex99-1.htm">&lsquo;US Defense Reports Broad Travelan&reg; Reactivity to 180 Pathogenic Bacteria including Camylobacter and Shigella&rsquo;</A></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Arial, Helvetica, Sans-Serif"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>IMMURON LIMITED</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Sans-Serif; font-size: 9pt; color: Red"><B></B></FONT><IMG SRC="img003.jpg" ALT="-S-Peter Vaughan"></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 52%"><FONT STYLE="font-size: 10pt">Date:&nbsp;&nbsp;January 29, 2018</FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 46%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Peter Vaughan</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Peter Vaughan</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Joint Chief Financial Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;&nbsp;</P>





<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Arial, Helvetica, Sans-Serif"></P></DIV>

    <!-- Field: /Page -->



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>s108836_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="color: Red; font: 10pt Sans-Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="color: Red; font: 10pt Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="color: Red; font: 10pt Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;<IMG SRC="img001.jpg" ALT="(GRAPHIC)"></P>

<P STYLE="color: Red; font: 10pt Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Calibri,sans-serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>US
Defense Reports Broad Travelan<SUP>&reg;</SUP> Reactivity to 180 </B></FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pathogenic Bacteria including Camylobacter and Shigella</B></FONT></P>

<P STYLE="font: 18pt Calibri,sans-serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Calibri,sans-serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><U>Key
Highlights:</U></I></B></FONT></P>

<P STYLE="font: 10pt Calibri,sans-serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial,sans-serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 14.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">The
                                         research program was performed by the U.S. Department of Defense (DoD) and was conducted
                                         by the Department of Enteric Diseases, </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Armed
                                         Forces Research Institute of Medical Sciences (AFRIMS) in Bangkok, Thailand.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,sans-serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial,sans-serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 14.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         major goal of the study was to evaluate Travelan<SUP>&reg;</SUP>&rsquo;s ability to bind
                                         and react to infectious bacteria of interest to the US DoD, including <I>Campylobacter</I>,
                                         ETEC and <I>Shigella</I> infections in Southeast Asia</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,sans-serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial,sans-serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 14.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         pathogenic bacteria were retrieved from infected personnel deployed in Bhutan, Cambodia,
                                         Nepal and Thailand</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,sans-serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial,sans-serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 14.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Results
                                         reported demonstrated Travelan<SUP>&reg;</SUP> was able to bind and was reactive to all
                                         180 strains of bacteria tested by Western blot analysis</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,sans-serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial,sans-serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 14.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Travelan<SUP>&reg;
                                         </SUP>showed particularly strong reactivity to 60 clinical isolates of personnel infected
                                         with ETEC and 60 personnel infected with <I>Shigella</I></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,sans-serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Calibri,sans-serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Melbourne,
Australia, January 30,</B> 2017: Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian microbiome biopharmaceutical company focused
on developing and commercializing oral immunotherapeutics for the treatment of many gut mediated diseases, today highlighted a
recent study on the immuno-reactivity of its commercially available and over-the-counter gastrointestinal and digestive health
supplement Travelan<SUP>&reg;</SUP> to infectious bacterium strains from Southeast Asia.</FONT></P>

<P STYLE="font: 10pt Calibri,sans-serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Calibri,sans-serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
study was commissioned by the US Department of Defense (DoD), funded by the Defense Health Agency&rsquo;s Defense Health Program
and performed at the Department of Enteric Diseases (DED), <FONT STYLE="background-color: white">Armed Forces Research Institute
of Medical Sciences </FONT>(AFRIMS), an overseas laboratory of the Walter Reed Army Institute of Research (WRAIR), located in
Bangkok, Thailand. The primary goal of this program was to investigate Travelan<SUP>&reg;</SUP> immunological reactivity with
pathogenic bacteria including <I>Campylobacter</I>, Enterotoxigenic <I>Escherichia coli</I> (ETEC) and <I>Shigella</I>. The tested
bacterial isolates originated from the AFRIMS&rsquo;s library of infectious diseases.</FONT></P>

<P STYLE="font: 10pt Calibri,sans-serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Calibri,sans-serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
evaluate the immuno-reactivity of Travelan<SUP>&reg;</SUP> 60 clinical isolates of each bacteria, <I>Campylobacter</I>, ETEC,
and <I>Shigella</I>, were tested by a Western blot analysis. The clinical isolates were collected from infected patients located
in Bhutan, Cambodia, Nepal and Thailand between 1993 and 2016, allowing researchers to measure the impact of Travelan<FONT STYLE="color: black"><SUP>&reg;
</SUP></FONT>antibodies on recent infectious bacterial strains in the field. When compared to the control, researchers found that
the antibodies within Immuron&rsquo;s Travelan<FONT STYLE="color: black"><SUP>&reg;</SUP></FONT> product were reactive to all
180 clinical isolates from these infected individuals. The ability of Travelan<FONT STYLE="color: black"><SUP>&reg;</SUP> </FONT>to
bind and potentially neutralise these bacteria, highlights the broad-spectrum recognition of surface antigens on potentially debilitating
and even life-threatening bacteria.</FONT></P>

<P STYLE="font: 10pt Calibri,sans-serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Calibri,sans-serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 31%; border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Arial,sans-serif; margin: 0pt 0; color: gray"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Arial,sans-serif; margin: 0pt 0; color: gray"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Level
        3, 62 Lygon Street,</FONT></P>
        <P STYLE="font: 10pt Arial,sans-serif; margin: 0pt 0; color: gray"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Carlton
        South, Victoria</FONT></P>
        <P STYLE="font: 10pt Arial,sans-serif; margin: 0pt 0; color: gray"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">AUSTRALIA
        3053</FONT></P></TD>
    <TD STYLE="width: 33%; border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="color: gray; font: 10pt Arial,sans-serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;&nbsp;</FONT></P>
        <P STYLE="color: gray; font: 10pt Arial,sans-serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><U>www.immuron.com</U></FONT></P>
        <P STYLE="color: gray; font: 10pt Arial,sans-serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>
        <P STYLE="color: gray; font: 10pt Arial,sans-serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">ABN:
        80 063 114 045</FONT></P></TD>
    <TD STYLE="width: 36%; border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="color: gray; font: 10pt Arial,sans-serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;&nbsp;</FONT></P>
        <P STYLE="color: gray; font: 10pt Arial,sans-serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Phone:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        + 61 (0)3 9824 5254</FONT></P>
        <P STYLE="font: 10pt Arial,sans-serif; margin: 0pt 0; text-align: right; color: gray"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Facsimile:
        + 61 (0)3 9822 7735</FONT></P></TD></TR>
</TABLE>


<P STYLE="font: 10pt Calibri,sans-serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Calibri,sans-serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Calibri,sans-serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%; border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 33%; border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"></TD>
    <TD STYLE="width: 33%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">
        <IMG SRC="img002.jpg" ALT="(GRAPHIC)"><P STYLE="font: 10pt Arial,sans-serif; margin: 0pt 0; text-align: right"></P></TD></TR>
</TABLE>


<P STYLE="font: 10pt Calibri,sans-serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Calibri,sans-serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Calibri,sans-serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CEO
of Immuron, Dr. Jerry Kanellos, said:&nbsp;</FONT></P>

<P STYLE="font: 10pt Calibri,sans-serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Calibri,sans-serif; margin: 0pt 13.8pt 0pt 14.2pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&ldquo;We
are pleased to see that Travelan<SUP>&reg;</SUP>, a product that has achieved significant sales growth, has proven its reactivity
to a multitude of clinically relevant bacterium strains within Southeast Asia including ETEC, Campylobacter and Shigella,&rdquo;
</I></FONT></P>

<P STYLE="font: 10pt Calibri,sans-serif; margin: 0pt 13.8pt 0pt 14.2pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Calibri,sans-serif; margin: 0pt 13.8pt 0pt 14.2pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
work completed at AFRIMS is the first of three research projects we are collaborating on with the US DoD. We hope to announce
the study results from the Department of Enteric Infections, US Naval Medical Research Center and the Department of Enteric Infections,
Bacterial Diseases Branch, WRAIR in the next few months. </I></FONT></P>

<P STYLE="font: 10pt Calibri,sans-serif; margin: 0pt 13.8pt 0pt 14.2pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Calibri,sans-serif; margin: 0pt 13.8pt 0pt 14.2pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Travelan&rsquo;s
reactivity to various forms of these infectious diseases makes it a valuable asset to foreign government officials looking to
protect employees stationed in these regions, as well as consumers who want to preserve their health while travelling abroad.
In addition to consumer purchases, government and organizational adoption of Travelan<SUP>&reg;</SUP> represents a significant
revenue opportunity for Immuron, and one that we seek to capitalize upon as we market the product more broadly.&rdquo; </I></FONT></P>

<P STYLE="font: 10pt Calibri,sans-serif; margin: 0pt 13.8pt 0pt 14.2pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Calibri,sans-serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
prophylactic treatment that protects against enteric diseases, specifically <I>Shigella</I>, is a high priority objective for
the US Army, supported under <FONT STYLE="background-color: white">Military Infectious Diseases Research Program, </FONT>and for
use in endemic areas of the world. <I>Shigella</I> in particular <FONT STYLE="background-color: white">is estimated to cause </FONT><U>80
&ndash;165 million cases of disease worldwide<FONT STYLE="background-color: white">, resulting in</FONT> 600,000 deaths annually</U> <FONT STYLE="background-color: white">and is particularly prevalent in both sub-Saharan Africa and South Asia.</FONT></FONT></P>

<P STYLE="font: 10pt Calibri,sans-serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Calibri,sans-serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
- - END - - -</FONT></P>

<P STYLE="font: 10pt Calibri,sans-serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 42%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="color: #0079C1; font: 10pt Calibri,sans-serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COMPANY
CONTACT:&nbsp;</B></FONT></P>
        <P STYLE="color: #231F20; font: 10pt Calibri,sans-serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="color: #231F20; font: 10pt Calibri,sans-serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jerry
Kanellos</B></FONT></P>
        <P STYLE="color: #231F20; font: 10pt Calibri,sans-serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
Executive Officer (Interim)</FONT></P>
        <P STYLE="color: #231F20; font: 10pt Calibri,sans-serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ph:
+61 (0)3 9824 5254</FONT></P>
        <P STYLE="color: #231F20; font: 10pt Calibri,sans-serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">jerrykanellos@immuron.com </FONT></P></TD>
    <TD STYLE="width: 20%; padding-right: -0.35pt; padding-left: 5.4pt; font: 10pt Times New Roman,serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 38%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Calibri,sans-serif; margin: 0pt 0; text-align: justify; color: #0079C1"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AUS
INVESTOR RELATIONS:</B></FONT></P>
        <P STYLE="font: 10pt Calibri,sans-serif; margin: 0pt 0; text-align: justify; color: #0079C1"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Calibri,sans-serif; margin: 0pt 0; text-align: justify; color: #231F20"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Peter
Taylor</B></FONT></P>
        <P STYLE="font: 10pt Calibri,sans-serif; margin: 0pt 0; text-align: justify; color: #231F20"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NWR
Communications</FONT></P>
        <P STYLE="font: 10pt Calibri,sans-serif; margin: 0pt 0; text-align: justify; color: #231F20"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ph:
+61 (0)4 1203 6231</FONT></P>
        <P STYLE="font: 10pt Calibri,sans-serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">peter@nwrcommunications.com.au</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman,serif; padding-right: -0.35pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Calibri,sans-serif; margin: 0pt 0; text-align: justify; color: #0079C1"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>USA
MEDIA CONTACT:</B></FONT></P>
        <P STYLE="font: 10pt Calibri,sans-serif; margin: 0pt 0; text-align: justify; color: #0079C1"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Calibri,sans-serif; margin: 0pt 0; text-align: justify; color: #231F20"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Kate
Caruso-Sharpe</B></FONT></P>
        <P STYLE="font: 10pt Calibri,sans-serif; margin: 0pt 0; text-align: justify; color: #231F20"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FischTank
Marketing and PR</FONT></P>
        <P STYLE="font: 10pt Calibri,sans-serif; margin: 0pt 0; text-align: justify; color: #231F20"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US
Ph: + 1 646 699 1414</FONT></P>
        <P STYLE="color: #231F20; font: 10pt Calibri,sans-serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">kate@fischtankpr.com</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman,serif; padding-right: -0.35pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Calibri,sans-serif; margin: 0pt 0; text-align: justify; color: #0079C1"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>USA
INVESTOR RELATIONS:</B></FONT></P>
        <P STYLE="font: 10pt Calibri,sans-serif; margin: 0pt 0; text-align: justify; color: #0079C1"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Calibri,sans-serif; margin: 0pt 0; text-align: justify; color: #231F20"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jon
Cunningham</B></FONT></P>
        <P STYLE="font: 10pt Calibri,sans-serif; margin: 0pt 0; text-align: justify; color: #231F20"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RedChip
Companies, Inc.</FONT></P>
        <P STYLE="font: 10pt Calibri,sans-serif; margin: 0pt 0; text-align: justify; color: #231F20"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US
Ph: +1 (407) 644 4256, (ext. 107)</FONT></P>
        <P STYLE="font: 10pt Calibri,sans-serif; margin: 0pt 0; text-align: justify; color: #231F20"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">jon@redchip.com</FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Calibri,sans-serif; margin: 0pt 0; text-align: justify; color: #231F20"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Calibri,sans-serif; margin: 0pt 0; text-align: justify; color: #231F20"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ABOUT
IMMURON:</B></FONT></P>

<P STYLE="font: 10pt Calibri,sans-serif; margin: 0pt 0; text-align: justify; color: #231F20"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immuron
Ltd (ASX: IMC) is a biopharmaceutical company focused on developing and commercialising oral immunotherapeutics for the treatment
of many gut mediated diseases. Immuron has a unique and safe technology platform that enables a shorter development therapeutic
cycle. The Company currently markets and sells Travelan<SUP>&reg;</SUP> for the prevention of traveler&rsquo;s diarrhea whilst
its lead product candidate IMM-124E is in Phase 2 clinical trials for NASH and ASH. These products together with the Company&rsquo;s
other preclinical immunotherapy pipeline products targeting immune-related diseases currently under development, will meet a large
unmet need in the market. For more information visit: <B>http://www.immuron.com</B></FONT></P>

<P STYLE="font: 10pt Calibri,sans-serif; margin: 0pt 0; text-align: justify; color: #231F20"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Calibri,sans-serif; margin: 0pt 0; text-align: justify; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: right; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2 <!-- Field: /Sequence -->of
                                                                                      3&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Calibri,sans-serif; margin: 0pt 0; text-align: justify; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; width: 34%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; width: 33%"></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; width: 33%; text-align: right">
        <IMG SRC="img002.jpg" ALT="(GRAPHIC)"><P STYLE="font: 10pt Arial,sans-serif; margin: 0pt 0; text-align: right"></P></TD></TR>
</TABLE>

<P STYLE="font: 10pt Calibri,sans-serif; margin: 0pt 0; text-align: justify; color: #231F20"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Calibri,sans-serif; margin: 0pt 0; text-align: justify; color: #231F20"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FORWARD-LOOKING
STATEMENTS:</B></FONT></P>

<P STYLE="color: #231F20; font: 10pt Calibri,sans-serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
statements made in this release are forward-looking statements and are based on Immuron&rsquo;s current expectations, estimates
and projections. Words such as &ldquo;anticipates,&rdquo; &ldquo;expects,&rdquo; &ldquo;intends,&rdquo; &ldquo;plans,&rdquo; &ldquo;believes,&rdquo;
&ldquo;seeks,&rdquo; &ldquo;estimates,&rdquo; &ldquo;guidance&rdquo; and similar expressions are intended to identify forward-looking
statements. Although Immuron believes the forward-looking statements are based on reasonable assumptions, they are subject to
certain risks and uncertainties, some of which are beyond Immuron&rsquo;s control, including those risks or uncertainties inherent
in the process of both developing and commercialising technology. As a result, actual results could materially differ from those
expressed or forecasted in the forward-looking statements. The forward-looking statements made in this release relate only to
events as of the date on which the statements are made. Immuron will not undertake any obligation to release publicly any revisions
or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date
of this release except as required by law or by any appropriate regulatory authority.</FONT></P>

<P STYLE="color: #231F20; font: 10pt Calibri,sans-serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: right; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->
                                                                                      of 3&nbsp;</P></DIV>

    <!-- Field: /Page -->


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img003.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ /0"6 P$1  (1 0,1 ?_$ '\   $#!0$!
M       '" D! @0%!@H# 0$!                     1    8" 0,# @0$
M!@,      0(#! 4&!P@1 !()(3$3(A1!414683(8"G&10B,D%U)#&1$!  $$
M P$               $1(3%!<8&1H?_:  P# 0 "$0,1 #\ ]_'0'0'0'04$
M0#W$ Y_,>.@!, <<C[B !_B/^'04 Q3<]I@'@>!X'G@>.>!X]AX_/H$:RGL3
M@3"+7[W,.:,4XN:@HFB*N0;]6*EPLLD*R"0$FY)FH*BR0"8A>.3![?AT#';-
MYB_'W%236'J>:'>:9QVK]NC#:_8\R%FMV(FX,*HK4.N2K B)#$ IA!80 P\>
M_/ 8Q_)G/V,B)\2^//R!9)(LX^T"2D<+P>*H?ZA.F1<SS*%WKCK[0%2_6?X.
M2%^K@>..@V#O:WR$RQCEIWC%DF*KB,%Q&/,D;38DKC1!Z')U6<VA ,;0Y9@8
M ^@Z(+B8?< Z#01.UWDWB3*M[WXOHE^*+E%91WBW;G&E@:#%J)&.H#=*S0%6
M=NI8JH< GVD3, A]70=%7O)(C"6R/J>R6INR^I;.4=M&J&3<I0-)G,*$=*D
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3#H#H#H#H#H#H#H#H#H#H#H/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img001.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ 20$( P$1  (1 0,1 ?_$ ,(   (# 0$! 0
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MW+Y41<,1@LY;1^9( 5JV-:+7&AIA,1&6XB$Y$L)0G)EY,,,*R)>XFI.U:4,
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MFN,R(#CB4/PDM)2GJU' A*N^QP[IIU)I$7(:5KWI#%K<WF#FH6]RE-7Z/B:
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M^?$AKGR8XD+:A-XYW5=$94X!1Y\>2I=/8'0R F@--JCO7%LC"!5=G\6-=?\
M@$_WW?\ 05Q^A%_VM].*Z_<D_P"L^G!2NM;E,N>S]SGS82[=*D0BMV"[CG:.
M<#*K$)/V*BMF!MR #4 XJ6=Q= 210T4WMSV#L'H+'B"H+S.=O*EMLMNY5;=(
M^::PT-<6$8RC<#&44\%*:<R@I)',,Q-6K';'(TX<JKW>Q[#VU3+I8KZ*$(H0
MBA"*$(H0BA"*$(H0BA"*$(H0BA"*$(H0BA"*$(H0BA"56\]RAVS4FB+A,7U<
M6)-=>?4 5$(062H@#B:;:<PN9(T8D?REU\X->PG '^%*'?C;4 DSW<!Q/Z.]
M_-J+_%S]WO"D_P A%W^Y1^Y,IF3J[;B2TK%I^<7&B>!*5EE0X'V#4EDTB.4?
M_/\ *XNC5\9]?\+UN&0-U=! GB7)& ]Q->6G]O+P1<YT:B=P42H>K9VG8R%=
M5K@0@%IQP0MIWJY!//TFAQPJ6TH8P\_BK_M[U'<U#RP?DI_NI/7C33&Y^W[#
M>"4-J>0VG[E*4@"H[4U@E.Y27 I-&O:R/_H1 QX_,QX??&O!_9_>C_T_:F7)
M_5G? 5\%+&XJ^<$N?5^(.@,0<1Y[(Y/O:9:MG< J.G9?%1V[%W@6?<31ESGN
M%N)$\X<>6 5$)Z(X)'$\34EA&7PR-&)HN+QX;*PG *;_ ([[;?Z^[_L[W\VH
M?\7/W>\*7_(1=_N7SU?JVQZGVIU%<+.\IZ*VTMA:UH4V0M.11&"P#R*%%O;O
MBN&!V*\FF;)"XMP45H[>30-KTI:;=+FN)EQ(K3+R$L.J 6A(! (3@>-37&G3
M.D<X#83WJ."]C:P G: OVW7&3N'KVVW6)&>8TOI[.ZS)=3D+\E0PX ]SN>Q[
M->/8+>(M)_J/]P7K7&:0. ^!O^J;%*4Q10A%"$4(10A%"$4(10A%"$4(10A%
M"$4(10A%"$4(10A%"$4(2SWI[RS^$_\  BFFF_-P5"^[$KE]XKVC30)<FWJ3
M]XZ#^51XK5*(>F7T[TSEQC73K#M[I/PW?M5S;Y+UU-F,73JGMMI7PY'B"N(,
MI_!=2YC>*YM8=OM)^&]]JN[?)>N9LQB%?6\CZ-^V:/\ S?<C\_!79_\ (N>"
M?@JB,5:*INT79+]I>^U5W4,S@JMGT<57]Z/U^U?)/>,BK&FX.4-]B$N:9*BF
M#IWZI[]\JYXK=+IO[AOIWJ[%DN5"C_K#/RB/&%,'8*F,5HFQ_NMCVC\)K-OQ
&*>,P7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>img002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img002.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ &P!: P$1  (1 0,1 ?_$ )X   (# 0$
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(D_V^GV]R_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
